Long-term effects of folic acid and vitamin-B12 supplementation on fracture risk and cardiovascular disease: Extended follow-up of the B-PROOF trial

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as a randomized controlled trial.

In the initial B-proof, the researchers found inconsistent results of B vitamin supplementation.

However, the debate regarding the effects of B vitamins on age-related diseases continues.

Therefore, their aim was to investigate the long-term effects (5-7 years follow-up) of an intervention with folic acid and vitamin-B12 supplementation on fracture and cardiovascular disease risk.

Who Took Part

By PubMed's age tags, the people studied were older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Cyanocobalamin (Vitamin B12) group and the comparison group should start out alike.

As a double-blind Cyanocobalamin (Vitamin B12) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Cyanocobalamin (Vitamin B12) group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Cardiovascular Diseases, Cerebrovascular Disorders, Dietary Supplements, Folic Acid, Fractures, Bone, Homocysteine and Odds Ratio.

Author keywords: B-vitamins and Long-term follow-up.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cyanocobalamin (Vitamin B12).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Clinical nutrition (Edinburgh, Scotland)), a journal based in England.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.